Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

By I. Raz, M. Hanefeld, L. Xu, C. Caria, D. WILLIAMS-HERMAN, H. Khatami, Sitagliptin Study 023 Group. Diabetologia, 2006

634 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Update on the treatment of type 2 diabetes mellitus. (2016, background): “Sitagliptin had a neutral effect on body weight [108] .”
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009, background): “DPP-4 inhibitors are small molecules that enhance the effects of GLP-1 and GIP, increasing glucose-mediated insulin secretion and suppressing glucagon secretion (83,84).”
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. (2007, background): “Indeed, the magnitude of the reduction in HbA1c with incretin therapy was dependent on the baseline HbA1c so that greater reductions were seen in groups of participants with higher baseline HbA1c.21,29,30 Incretin therapy decreased both fasting and postprandial glycemia; however, improvements in pos”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Furthermore, 200 mg daily did not inhibit DPP4 activity any more than did the 100-mg dose (Raz et al., 2006).”